US 11,898,178 B2
Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
Shengjiang Liu, Hayward, CA (US)
Assigned to AVIRMAX, INC., Hayward, CA (US)
Filed by AVIRMAX, INC., Hayward, CA (US)
Filed on Aug. 29, 2022, as Appl. No. 17/823,066.
Application 17/823,066 is a continuation of application No. 17/368,755, filed on Jul. 6, 2021, granted, now 11,453,869.
Claims priority of provisional application 63/093,788, filed on Oct. 19, 2020.
Claims priority of provisional application 63/048,645, filed on Jul. 6, 2020.
Prior Publication US 2022/0411772 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/48 (2006.01); C12N 15/86 (2006.01)
CPC C12N 9/485 (2013.01) [C12N 15/86 (2013.01); C12Y 304/17023 (2013.01)] 5 Claims
 
1. An isolated polynucleotide comprising SEQ ID NOs: 64, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80 or 81.